[Inhibitors of proton pump in the treatment of non-ulcer functional dyspepsia of the reflux-like type].
The results of two treatment types of the patients with chronic gastritis and with non-ulcerative functional dyspepsia (NFD) at reflux-similar variant are represented. The patients received Omeprasol (Losec) or Rabeprasol (Pariet) accordingly 20 mg once per day in the morning, 30-60 minutes before the breakfast. The treatment course was 7 days. The investigations have shown the following: the level of acidity has decreased in all the patients treated by Rabeprasol, normal acidity is detected in the all 15 patients, the level of gastric acidity has decreased in the patients, treated by Omeprasol. However the hyperacidity was preserved in 10 from 12 patients.
Ivanova
N G
NG
Central Research Institute of Gastroenterology, Moscow.
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000293:Adolescent; D000328:Adult; D001562:Benzimidazoles / Q000627:therapeutic use*; D004415:Dyspepsia / Q000175:diagnosis / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D004942:Esophagitis, Peptic / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use*; D054328:Proton Pump Inhibitors; D064750:Rabeprazole
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D064750:Rabeprazole; D009853:Omeprazole
Ingibitory protonnogo nasosa v terapii neiazvennoĭ funktsional'noĭ dispepsii pri refliuksno-podobnom variante.